Long-lasting tumor regression was observed after combined inhibition of EGFR and HER2 in cetuximab-resistant, KRAS-, NRAS-, BRAF-, PIK3CA-wt, and HER2-amplified metastatic CRC [55]. Here, ERBB2 is linked to neoplasm.